Abstract: The histone acetyltransferases p300 and CBP are critical epigenetic regulators that drive the transcription of key oncogenes in various cancers, including hematological malignancies. Inobrodib, also known as CCS1477, is a potent and specific small-molecule inhibitor targeting the bromodomains of p300 and CBP. By competitively inhibiting acetylated lysine binding, Inobrodib suppresses the expression of oncogenes such as MYC, MYB, and FGFR3. In preclinical models of acute myeloid leukemia (AML) and multiple myeloma, Inobrodib induces cell differentiation and halts cancer progression, both as a monotherapy and in combination with standard-of-care agents. Early-stage clinical trials in patients with relapsed or refractory AML and multiple myeloma have demonstrated encouraging therapeutic responses, including sustained progression-free survival and significant reductions in disease biomarkers. This review summarizes the pharmacological activity, molecular mechanism, structure-activity relationship, limitations, and future perspectives of Inobrodib in the treatment of leukemia and lymphoma.
1. Introduction
The histone acetyltransferases p300 (E1A-associated protein p300) and CBP (CREB binding protein) are highly conserved epigenetic regulators that catalyze the acetylation of histone H3 at lysine 27 (H3K27). This epigenetic modification opens chromatin structures at promoters, enhancers, and super-enhancers, thereby facilitating the recruitment of RNA Polymerase II and activating gene transcription [1]. In hematological malignancies such as leukemia and lymphoma, the overexpression or aberrant activation of p300/CBP plays a crucial role in malignant transformation, cell proliferation, and the maintenance of leukemia stem cells by driving the transcription of pivotal oncogenes like MYC and MYB [1].
Targeting epigenetic modulators has historically been challenging due to the highly conserved nature of protein domains and the risk of off-target effects. However, recent advancements have led to the discovery of specific small-molecule inhibitors. Inobrodib, designated as CCS1477 in preclinical and early clinical development, has emerged as a highly potent p300/CBP bromodomain inhibitor. It is currently under clinical investigation for advanced solid tumors and hematological malignancies, representing a promising targeted therapeutic strategy for leukemia and lymphoma [1].
2. Pharmacological Activity
Inobrodib (CCS1477) exhibits robust pharmacological activity against hematological malignancies in both preclinical models and clinical trials. In acute myeloid leukemia (AML) and multiple myeloma cells, CCS1477 effectively downregulates the expression of MYB and FGFR3 target genes, leading to the induction of cancer cell differentiation [1]. Furthermore, combination therapy utilizing CCS1477 alongside standard-of-care agents has been shown to successfully block cancer progression across multiple mouse models [1].
In specific subtypes of AML characterized by myelodysplastic syndrome, CBP is a key factor mediating resistance to the DNA methylation inhibitor azacytidine. In this context, combination therapy with CCS1477 and the p300/CBP HAT inhibitor A-485 synergistically reduces the expression of protein synthesis genes and displays synergistic anticancer effects with azacytidine [1].
Clinically, Inobrodib is being evaluated in a Phase I/IIa clinical trial (ClinicalTrials.gov Identifier: NCT04068597) for patients with relapsed or refractory AML and multiple myeloma. Early data are highly encouraging: CCS1477 induces leukemia cell differentiation in AML patients and causes substantial reductions in serum and urinary biomarkers in myeloma patients who had previously failed multiple other treatments. Approximately one-third of the patients in this trial demonstrated a therapeutic response to CCS1477 monotherapy, with progression-free survival sustained for more than 12 months in some cases [1].
3. Molecular Mechanism of Action
The molecular mechanism of Inobrodib (CCS1477) centers on its function as a specific and potent acetylated lysine competitive protein-protein interaction inhibitor targeting the bromodomains of p300 and CBP [1]. The bromodomain is essential for p300/CBP-dependent H3K27 acetylation and subsequent gene transcription. By binding to these bromodomains, CCS1477 prevents p300/CBP from interacting with acetylated histones and transcription factors at enhancer and super-enhancer regions [1].
This blockade results in a reduction of H3K27 acetylation and the profound transcriptional repression of key oncogenes. In the context of leukemia and myeloma, CCS1477 specifically represses the expression and signaling of MYB, MYC, and FGFR3, which are critical drivers of cancer cell multiplication and survival. By dismantling the enhancer-mediated transcription of these oncogenes, Inobrodib induces cell cycle arrest, promotes cellular differentiation, and halts tumor progression [1].
4. Structure-Activity Relationship (SAR)
Inobrodib (CCS1477) was developed as a highly specific inhibitor with exceptional binding affinity for its targets. It suppresses p300 and CBP with dissociation constant (KD) values of 1.3 nM and 1.7 nM, respectively, demonstrating its high potency at low nanomolar concentrations [1]. Its structural properties allow it to act as a competitive inhibitor of acetylated lysine, effectively disrupting the bromodomain's protein-protein interactions.
Furthermore, the optimized chemical scaffold of CCS1477 has proven valuable in the development of next-generation therapeutics. The structure of CCS1477 was utilized as the parental targeting ligand to design proteolysis-targeting chimeras (PROTACs), such as QC-182. By linking the CCS1477 bromodomain-binding moiety to an E3 ligase recruiter, researchers successfully created PROTACs that not only inhibit but actively induce the ubiquitination and degradation of p300/CBP proteins [1].
5. Current Limitations
Despite the promising preclinical and early clinical efficacy of Inobrodib, several limitations remain. While the Phase I/IIa clinical trials in hematological malignancies are ongoing and early data are encouraging, the comprehensive safety profiles and adverse event data for CCS1477 have not yet been fully disclosed [1]. Additionally, any potential mechanisms of acquired or intrinsic cancer cell resistance to CCS1477 monotherapy remain unknown and have not been reported in the current literature [1]. Furthermore, there is a general lack of reported systematic toxicology studies (such as detailed blood, liver, and kidney toxicity analyses) in preclinical mouse models for this specific class of inhibitors [1].
6. Future Perspectives
The future development of Inobrodib (CCS1477) and related p300/CBP inhibitors should prioritize overcoming potential resistance and maximizing therapeutic indices. Future research must establish in vitro and in vivo models of cancer cell resistance to understand the underlying mechanisms and explore alternative targets within the p300/CBP oncogenic pathway [1].
Combination therapies represent a highly promising avenue. Preclinical evidence already suggests that combining CCS1477 with standard-of-care agents, DNA methylation inhibitors (like azacytidine), or other epigenetic modulators (like the HAT inhibitor A-485) can yield synergistic effects, particularly in resistant phenotypes such as AML with myelodysplastic syndrome [1]. Identifying the most efficacious combination strategies through CRISPR-Cas9 screening and drug library screens will be crucial for clinical translation. Finally, the evolution of CCS1477 into PROTAC degraders (e.g., QC-182) highlights a future direction where targeted protein degradation may offer superior efficacy and specificity compared to traditional enzymatic or bromodomain inhibition [1].
